Evidence review
Tesamorelin: The Peptide That Actually Has an Approval and a Trial Programme
Tesamorelin is FDA-approved as Egrifta for reducing excess abdominal fat in people with HIV-associated lipodystrophy. That is a narrow indication with a real trial progra
Tesamorelin is FDA-approved as Egrifta for reducing excess abdominal fat in people with HIV-associated lipodystrophy. That is a narrow indication with a real trial programme behind it — and it is the reason tesamorelin is a useful reference point for judging every other peptide marketed for body composition.
Why this one is different
Most peptides marketed for body composition have mechanistic rationale and little else. Tesamorelin has an FDA approval, a defined indication, and randomised trials that measured visceral adipose tissue by CT rather than by self-report.
That makes it the natural benchmark. When a provider markets a growth-hormone secretagogue for fat loss, the useful question is: how does the evidence compare with tesamorelin's, which exists and is public?
What the approval actually covers
Reduction of excess abdominal fat in adults with HIV infection and lipodystrophy. That is a specific population with a specific pathophysiology — antiretroviral-associated fat redistribution — and the trials were conducted in it.
Use outside that population is off-label. Off-label prescribing is lawful and often appropriate, but the evidence supporting it is extrapolation rather than demonstration, and it should be described that way.
Where this sits on the evidence ladder
We grade every claim in this category against four tiers, because collapsing them is how peptide marketing works.
Tier 1 — approved drug. Premarket review of safety, effectiveness and manufacturing quality. A registry number and a peer-reviewed publication behind each indication.
Tier 2 — human randomised trials, hard endpoints. Not approved for the marketed use, but tested in people against a comparator on something a patient would notice.
Tier 3 — human data without controls. Open-label series, biomarker studies, small uncontrolled cohorts. Useful for generating hypotheses, unreliable for estimating effect.
Tier 4 — animal and mechanistic work. Where most peptide marketing draws its citations. The attrition rate between promising rodent data and demonstrated human benefit is very high across all of pharmacology.
What the trials showed, and what they measured
Tesamorelin reduced visceral adipose tissue measured by CT scan, alongside changes in triglycerides and IGF-1. Visceral fat is the metabolically consequential depot — the one associated with insulin resistance, inflammation and cardiovascular risk — so measuring it directly rather than measuring weight is a meaningfully better endpoint.
What the programme did not establish is that reducing visceral fat in this population reduces cardiovascular events. That is the standard surrogate-versus-outcome gap, and it applies here as it does across metabolic medicine.
How it compares with a GLP-1
Different mechanism, different indication, and a very different evidence base in scale. Tirzepatide has SURMOUNT-1 through SURMOUNT-5 plus SURPASS-CVOT and SUMMIT — tens of thousands of randomised participants across weight, glycaemia, cardiovascular and heart-failure endpoints.
SYNCHRONIZE-1 reported 16.6% weight loss alongside a 34% reduction in visceral fat and 63% in liver fat, which is the closest direct comparison on the measure tesamorelin was approved on. That does not make one better than the other for any individual — they are approved for different things — but it does mean a provider marketing tesamorelin as a body-composition alternative to GLP-1s is comparing against a much larger evidence base.
The cost question
Tesamorelin as an approved product carries approved-product pricing, which is substantially higher than compounded peptide programmes. Compounded versions exist and are not the approved product; the trial evidence attaches to the approved formulation.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Search intent match | Does the page answer the question actually being asked? |
| 2 | Original value test | What exists here that is not already on ten other sites? |
| 3 | Source and evidence review | Every claim resolves to a ledger entry with a capture date. |
| 4 | Medical review | A named clinician checks claims against their primary sources. |
| 5 | Pricing verification | Figures re-captured from the provider's own page, dated. |
| 6 | Conflict-of-interest review | Any relationship that could bias the page, declared. |
| 7 | Legal and regulatory language | No implied approval, no generic claim, no individual advice. |
| 8 | Accessibility review | WCAG 2.2 AA, keyboard, contrast, chart data tables. |
| 9 | Mobile QA | 390px viewport hides no fee, qualifier, status or date. |
| 10 | Structured-data validation | JSON-LD matches what a reader can see. |
| 11 | Internal-link validation | Parent hub, methodology, siblings, tool or dataset. |
| 12 | Duplication and cannibalisation check | No two pages chasing the same intent. |
| 13 | Date and cadence assignment | Review dates set from real work, not from the calendar. |
| Date | What happened | Effect on compounded access |
|---|---|---|
| 2022 | Tirzepatide added to the FDA drug shortage list | A shortage listing is what permitted compounders to make copies of the approved product. |
| 2024-10 | FDA declared the tirzepatide shortage resolved | Removing the shortage listing removed one of the two legal pathways for compounding tirzepatide. |
| 2025-02 | FDA declared the semaglutide shortage resolved | The same pathway closed for semaglutide four months later. |
| 2025-09-16 | FDA issued 55+ warning letters to online GLP-1 sellers | Letters cited misleading direct-to-consumer advertising of compounded GLP-1 products. |
| 2026-02-09 | Novo Nordisk sued Hims & Hers over compounded semaglutide | Patent infringement claim following the launch of a low-cost compounded oral product. |
| 2026-03-03 | FDA released 30 further warning letters to telehealth firms | Targeting claims that compounded GLP-1s are equivalent to the branded products. |
| 2026-03-09 | Hims & Hers settled with Novo Nordisk and pivoted to branded supply | Hims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market. |
| 2026-04-30 | FDA proposed excluding tirzepatide from the 503B bulks list | The agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway. |
| 2026-05-01 | Formal notice published at 91 Fed. Reg. 23431 | Docket 2026-08552 sets out the agency's substance-by-substance reasoning. |
| 2026-06-26 | Comment period extended to 30 July 2026 | FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination. |
| 2026-07-30 | Comment period closes | After this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026. |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
Questions readers actually ask
Is tesamorelin FDA-approved?
Yes, as Egrifta, for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Can tesamorelin be used for general fat loss?
That is off-label. The trials were conducted in HIV-associated lipodystrophy, and use outside that population is extrapolation.
Is compounded tesamorelin the same as Egrifta?
No. A compounded preparation is not the approved product and has not been through premarket review. The trial evidence attaches to the approved formulation.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- GLP-1 Tirzepatide Reviews: Evidence, Prices, Providers & ToolsCore & Trust
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Oak Longevity Tirzepatide ReviewProviders
- Noom Med Tirzepatide ReviewProviders
Related coverage
GLP-1 Tirzepatide Reviews. “Tesamorelin: The Peptide That Actually Has an Approval and a Trial Programme.” S.J Partners LLC, 2026-07-24. https://glptirzepatidereviews.com/peptides/tesamorelin/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.